Singapore markets open in 6 hours 25 minutes

Aclaris Therapeutics, Inc. (ACRS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.0550-0.0550 (-4.98%)
As of 02:35PM EDT. Market open.

Aclaris Therapeutics, Inc.

701 Lee Road
Suite 103
Wayne, PA 19087
United States
484 324 7933
https://www.aclaristx.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees86

Key executives

NameTitlePayExercisedYear born
Dr. Neal S. Walker D.O., M.D.Co-Founder, President, Chairman & Interim CEO73.5kN/A1970
Mr. Kevin BalthaserChief Financial Officer581.52kN/A1988
Dr. Joseph Monahan Ph.D.Chief Scientific Officer492.43kN/A1957
Mr. James LoeropChief Business Officer570kN/A1965
Mr. Matthew Rothman J.D.General Counsel & Corporate SecretaryN/AN/AN/A
Dr. Jon Jacobsen Ph.D.Senior Vice President of ChemistryN/AN/AN/A
Mr. Steve TuckerSenior Vice President of Project LeadershipN/AN/AN/A
Mr. Ajay Aggarwal M.B.A., M.D.Senior Vice President of Clinical DevelopmentN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Corporate governance

Aclaris Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.